

Published manuscripts

1. Morrisroe K, Nikpour M. **Cancer and scleroderma: recent insights**. *Curr Opin Rheumatol* 2020. Accepted May 23.
2. Morrisroe K, Nikpour M. **Advances and controversies in connective tissue disease related pulmonary arterial hypertension**. *Int J Rheum Dis* 2020. Accepted May 22.
3. Patel S, Morrisroe K, Proudman S, Hansen D, Sahhar J, Sim MR, Ngian G-S, Walker J, Strickland G, Wilson M, Ferdowsi N, Major G, Roddy J, Stevens W, Nikpour M and the Australian Scleroderma Interest Group. **Occupational Silica Exposure in an Australian Systemic Sclerosis Cohort**. *Rheumatology (Oxford)* 2020. Accepted May 15.
4. Fortuné C, Gietzen A, Guillot G, Lewis N, Nielsen K, Richard M, Sauvé M, Welling J; SPIN Investigators, Baron M, Furst DE, Gottesman K, Malcarne V, Mayes MD, Mouthon L, Nielson WR, Riggs R, Wigley F, Assassi S, Boutron I, Ells C, van den Ende C, Fligelstone K, Frech T, Godard D, Harel D, Hinchcliff M, Hudson M, Johnson SR, Larche M, Leite C, Nguyen C, Pope J, Portales A, Rannou F, Reyna TSR, Schouffoer AA, Suarez-Almazor ME, Agard C, Albert A, André M, Arsenault G, Benzidia I, Bernstein EJ, Berthier S, Bissonnette L, Boire G, Bruns A, Carreira P, Casadevall M, Chaigne B, Chung L, Cohen P, Correia C, Dagenais P, Denton C, Domsic R, Dubois S, Dunne JV, Dunogue B, Fare R, Farge-Bancel D, Fortin PR, Gill A, Gordon J, Granel-Rey B, Gyger G, Hachulla E, Hatron PY, Herrick AL, Hij A, Hoa S, Ikic A, Jones N, Fernandes AJB, Kafaja S, Khalidi N, Lambert M, Launay D, Liang P, Maillard H, Maltez N, Manning J, Marie I, Martin M, Martin T, Masetto A, Maurier F, Mekinian A, Melchor S, Nikpour M, Olagne L, Poindron V, Proudman S, Régent A, Rivière S, Robinson D, Rodriguez E, Roux S, Smets P, Smith D, Sobanski V, Spiera R, Steen V, Stevens W, Sutton E, Terrier B, Thorne C, Varga J, Wilcox P, Ayala MC, Ostbo N, Thombs BD, Kwakkenbos L, Carrier ME, Bourgeault A, Tao L, Harb S, Gagarine M, Rice D, Bustamante L, Ellis K, Duchek D, Wu Y, Bhandari PM, Neupane D, Carboni-Jiménez A, Henry RS, Krishnan A, Sun Y, Levis B, He C, Turner KA, Benedetti A, Culos-Reed N, El-Baalbaki G, Hebblethwaite S, Bartlett SJ, Dyas L, Patten S, Varga J; Scleroderma Patient-centered Intervention Network (SPIN); COVID-19 Patient Advisory Team. **Protocol for a Partially Nested Randomised Controlled Trial to Evaluate the Effectiveness of the Scleroderma Patient-Centered Intervention Network COVID-19 Home-Isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients**. *J Psychosom Res* 2020 May 14:110132.
5. Brown Z, Nikpour M. **Scleroderma: perspectives on a complex multi-organ autoimmune disease**. *Medicine Today* 2020. Accepted April 8.
6. Ross L, Stevens W, Wilson M, Huq M, Strickland G, Walker J, Sahhar J, Ngian G-S, Roddy J, Youssef P, Proudman S, Nikpour M. **Performance of the 2017 EUSTAR Activity Index in an Australian Scleroderma Cohort**. *Clinical Rheum* 2020. Accepted April 1.
7. Fairley JL, Hansen D, Proudman SM, Sahhar J, Ngian G-S, Walker J, Strickland G, Wilson M, Morrisroe K, Ferdowsi N, Major G, Roddy J, Stevens W, Nikpour M, for The Australian Scleroderma Interest Group. **Clinical characteristics and survival in systemic sclerosis-mixed connective tissue disease and systemic sclerosis-overlap syndrome**. *Arthritis Care Res*. 2020; Feb 14. doi: 10.1002/acr.24167. [Epub ahead of print]
8. Morrisroe K, Stevens W, Sahhar J, Ngian G-S, Ferdowsi N, Hill C.L, Hansen D, Patel S, Roddy J, Walker J, Proudman S, Nikpour M. **The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia**. *BMC Pulmonary Medicine*. 2019; 19:266.
9. Morrisroe K, Stevens W, Sahhar J, Ngian G-S, Ferdowsi N, Hill C.L, Roddy J, Walker J, Proudman S, Nikpour M. **Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics and associated clinical and economic burden**. *Arthritis Res Ther*. 2019; 21(1):299.
10. Morrisroe K, Stevens W, Sahhar J, Ngian G-S, Ferdowsi N, Hill C.L, Hansen D, Patel S, Roddy J, Walker J, Proudman S, Nikpour M. **The clinical and economic burden of systemic sclerosis related interstitial lung disease**. *Rheumatology (Oxford)* 2019 Nov 18. pii: kez532. doi: 10.1093/rheumatology/kez532. [Epub ahead of print]

11. Lopez-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy A, Granja J, Mumbach M, Beretta L, Simeon C, Carreira P, Ortego N, Castellvi I, Bossini-Catillo L, Carmona FD, Orozco G, Hunzelmann N, Distler J, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman B, Nordin A, Padyukov L, Hoffmann-Vold A, Lie B, European Scleroderma Group, Proudman S, Stevens W, Nikpour M, Australian Scleroderma Interest Group (ASIG), Vyse T, Herrick A, Worthington J, Denton C, Allanore Y, Brown M, Radstake T, Fonseca C, Chang H, Mayes M, and Martín J. **GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.** *Nature communications*. 2019; 10.1: 1-14.
12. Ross L, Stevens W, Wilson M, Strickland G, Walker J, Sahhar J, Ngian GS, Roddy J, Major G, Proudman S, Baron M, Nikpour M. **Can patient-reported symptoms be used to measure disease activity in systemic sclerosis?** *Arthritis Care Res (Hoboken)* 2019 Aug 17. doi: 10.1002/acr.24053. Online ahead of print.
13. Morrisroe K, Hansen D, Huq M, Stevens W, Sahhar J, Ngian G-S, Ferdowsi N, Hill C, Roddy J, Walker J, Proudman S, Nikpour M. **Incidence, risk factors and outcomes of cancer in systemic sclerosis.** *Arthritis Care Res (Hoboken)* 2019 Sep 20. doi: 10.1002/acr.24076. [Epub ahead of print]
14. Metwally M, Thabet K, Bayoumi A, Nikpour M, Stevens W, Sahhar J, Zochling J, Roddy J, Tymms K, Strickland G, Lester S, Rischmueller M, Ngian G-S, Walker J, Hissaria P, Shaker O, Liddle C, Manolios N, Beretta L, Proudman S, George J, and Eslam M. **IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis.** *Sci Rep*. 2019; 16;9(1):1-5.
15. Morrisroe K, Baron M, Frech T, Nikpour M. **Small intestinal bacterial overgrowth in systemic sclerosis** *Scleroderma Relat Disord*. 2019; Jul 29:2397198319863953.
16. Brown Z, Nikpour M. **Screening for Pulmonary Arterial Hypertension in Systemic Sclerosis, Now or Never!** *Eur J Rheumatol* 2019; Jul 29.
17. Abbot S, McWilliams L, Spargo L, de Costa C, Ur-Rehman Z, Proudman S, Bossingham D. **Scleroderma in Cairns: an epidemiological study.** *Intern Med J*. 2019; Jun 3.
18. Ross L, Nikpour M. **Gaining the upper hand on scleroderma digital ulcers?** *J Rheumatol* 2019 Jun; 46(6):548-549.
19. Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman S, The Scleroderma Clinical Trials Consortium Damage index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group, Baron M*, Nikpour M* (* equal contributors). **Development and validation of the scleroderma clinical trials consortium damage index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.** *Ann Rheum Dis* 2019. Jun;78(6):807-816.
20. Ferdowsi N, Stevens W, Baron M, Nikpour M. **Damage indices in rheumatic diseases: A systematic review of the literature.** *Sem Arthritis Rheum* 2019; 45(1):27-34.
21. Lin E, Vincent FB, Sahhar J, Ngian GS, Kandane-Rathnayake R, Mende R, Morand E, Lang T, Harris J. **Analysis of serum interleukin (IL)-1a, IL-1b and IL-18 in patients with systemic sclerosis.** *Clin & Transl Immunol*. 2019; 8(4):e1045.
22. Moxey J, Huq M, Proudman S, Sahhar J, Ngian G-S, Walker J, Strickland G, Wilson M, Ross L, Major G, Roddy J, Stevens W, Nikpour M. **Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.** *Arthritis Res Ther* 2019; 2019 Feb 14;21(1):57.
23. Quinlivan A, Proudman S, Sahhar J, Stevens W, Nikpour M on behalf of Australian Scleroderma Interest Group (ASIG). **Cost savings with a novel algorithm for early detection of systemic sclerosis-related pulmonary arterial hypertension: alternate scenario analyses.** *Intern Med J*. 2019; Jun 49(6):781-785
24. Baron M, Kahaleh B, Bernstein E, Chung L, Clements P, Denton C, Domsic R, Ferdowsi N, Foeldvari I, Frech T, Gordon J, Hudson M, Johnson S, Khanna D, McMahon Z, Merkel P, Sonali N, Nikpour M, Pauling J, Ross L, Vergara A, Vacca A. **An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.** *J Scleroderma Relat Disord* 2019; 4(1): 17-27.
25. Ross L, Prior D, Proudman S, Vacca A, Baron M, Nikpour M. **Defining primary systemic sclerosis heart involvement: a scoping literature review.** *Sem Arthritis Rheum* 2018 Jul 31. pii: S0049-0172(18)30312-3. doi: 10.1016/j.semarthrit.2018.07.008. [Epub ahead of print] Review.
26. Nikpour M. **Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to 'Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome?' by Coudrec et al.** *Ann Rheum Dis* 2019 Jun 12. pii: annrheumdis-2019-

215797. doi: 10.1136/annrheumdis-2019-215797
27. Nikpour M; Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) Working Group. **Disease activity and organ damage: different sides of the same coin in systemic sclerosis.** *Ann Rheum Dis* 2019 May 22. pii: annrheumdis-2019-215639. doi: 10.1136/annrheumdis-2019-215639.
28. Butler E, Baron M, Fogo A, Frech T, Ghossein C, Hachulla E, Hoa S, Johnson S, Khanna D, Mouthon L, Nikpour M, Proudman S, Steen V, Stern E, Varga J, Denton C, Hudson M. **Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology.** *Arthritis Rheum* 2019 Jan 7. doi: 10.1002/art.40809. [Epub ahead of print]
29. Nikpour M, Calderone A, Host L, Cannell P, Roddy J. **Letter to the Editor Regarding Shouval R, Furie N, Raanani P, Nagler A and Gafter-Gvili A. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.** *Biol Blood Marrow Transplant* 2018; 24:937-944. *Biol Blood Marrow Transplant* 2019 Jan 4. pii: S1083-8791(19)30002-3. doi:10.1016/j.bbmt.2018.12.838.
30. Patel S, Ross L, McKelvie P, Nikpour M. **Constrictive pericarditis as the presenting manifestation of systemic sclerosis.** *Rheumatology (Oxford)* 2018 Dec 24. doi: 10.1093/rheumatology/key404.
31. Richard N, Hudson M, Wang M, Gyger G, Proudman S, Stevens W, Nikpour M, Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG), Murray Baron. **Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.** *Rheum (Oxford)* 2018 Dec 4. doi: 10.1093/rheumatology/key350. [Epub ahead of print]
32. Vincent FB, Lin E, Sahhar J, Ngian GS, Kandane-Rathnayake R, Mende R, Hoi AY, Morand EF, Lang T, Harris J, **Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis.** *Clin & Transl Immunol* 2018; 7(12):e1042.
33. Ross L, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Walker J, Sahhar J, Ngian G-S, Zochling J, Roddy J, Tymms K, Major G, Strickland G, Proudman S, Nikpour M. **The Role of Inflammatory Markers in Assessment of Disease Activity in Systemic Sclerosis.** *Clin Exp Rheumatol* 2018 Jul-Aug; 36(Suppl.113):S126-S134.
34. Ross L, Baron M, Nikpour M. **The challenges and controversies of measuring disease activity in systemic sclerosis.** *J Scleroderma Relat Disord* 2018; 3(2):115-121.
35. Morrisroe K, Hudson M, Baron M, de Vries-Bowstra J, Carreira P, Wuttge DM, Wang M, Frech T, Stevens W, Proudman SM, Nikpour M for the International Systemic Sclerosis Inception Cohort (INSYNC) collaboration. **Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort.** *Clin Exp Rheumatol.* 2018 Jul-Aug; 36(Suppl.113):S53-60.
36. Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, Ingegnoli F, McHugh NJ, Johnson SR, Hudson M, Boin F, Ong VH, Matucci-Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL. **Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.** *J Scleroderma Relat Disord* 2018; 3(3): 249-252
37. Thakkar V, Patterson K.A, Stevens W, Wilson M, Roddy J, Sahhar J, Proudman S, Hissaria P, Nikpour M. **Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations.** *Clinical Rheum.* 2018; 37:1563-1571.
38. Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuța C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP. **Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.** *Ann Rheum Dis* 2018;77(4):563-570.
39. Fernández-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algorithm Group **Real-life treatment algorithms for systemic sclerosis according to experts.** *Arthritis Rheumatol.* 2017; 69(Suppl 10)

40. Proudman S, Huq M, Stevens W, Wilson ME, Sahhar J, Baron M, Hudson M, Pope J, Allanore Y, Distler O, Kowal-Bielecka O, Matucci Cerinic M, Low AHL, Teng GG, Santosa A, Nikpour M; ASIG, CSRG, EUSTAR, SCORE. **What have multi-centre registries across the world taught us about the disease features of systemic sclerosis?** *J Scleroderma Relat Disord* 2017; 2(3):135-234.
41. Morrisroe K, Stevens W, Sahhar J, Ngian G-S, Rabusa C, Ferdowsi N, Hill C, Proudman S, Nikpour M. **Quantifying the direct public health care cost of systemic sclerosis: a comprehensive data linkage study.** *Medicine (Baltimore)* 2017; 96(48): e8503.
42. Morrisroe K, V Sudararajan, W Stevens, J Sahhar, J Zochling, J Roddy, S Proudman, Nikpour M. **Work productivity in systemic sclerosis, its economic burden and association with health related quality of life.** *Rheumatology (Oxford)* 2017; 57(1):73-83.
43. Morrisroe K, Stevens W, Huq M, Sahhar J, Ngian G-S, Zochling J, Roddy J, the Australian Scleroderma Interest Group (ASIG), Proudman S, Nikpour M. **Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis.** *J Scleroderma Rel Dis* 2017; Accepted May 13. DOI: 10.5301/jsrd.5000243
44. Tay T, Huq M, Ferdowsi N, Stevens W, Sahhar J, Ngian G-S, Roddy J, Zochling J, Walker J, Proudman S, Nikpour M. **Early accrual of organ damage in systemic sclerosis: rationale for development of a disease damage index.** *J Scleroderma Relat Disord* 2017; 2(2):127-134.
45. Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, Celermajer D, Zochling J, Proudman S, Nikpour M; Australian Scleroderma Interest Group (ASIG). **Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension.** *Arthritis Research Therapy* 2017 Jun 2;19(1):122. doi: 10.1186/s13075-017-1341-x.
46. Morrisroe K, Stevens W, Huq M, Sahhar J, Ngian GS, Zochling J, Roddy J, Proudman SM, Nikpour M; Australian Scleroderma Interest Group (ASIG). **Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis.** *Clin Exp Rheumatol.* 2017 Sep-Oct ;35(Suppl 106):S130-137.
47. Nikpour M, Proudman S, Morrisroe K, Sahhar J, Stevens W. **The Australian Scleroderma Interest Group and Database: 10 years of screening to save lives.** *Medical Journal of Australia.* Letters to the Editor. 2017;206(5):229.
48. Morrisroe K, Nikpour M*, Proudman S*, the Australian Scleroderma Interest Group (ASIG) (*contributed equally). **Epidemiology and disease characteristics of systemic sclerosis related pulmonary arterial hypertension: results from a real life screening program.** *Arthritis Research Therapy.* 2017;19:42.
49. Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, Tatibouet S, Carmona L, Joven B, Huq M, Proudman S, Nikpour M. **Early mortality in a multinational systemic sclerosis inception cohort.** *Arthritis & Rheumatology.* 2017 May;69(5):1067-1077. doi: 10.1002/art.40027. Epub 2017 Apr 6.
Featured in the Year-in-Review research highlights of the American College of Rheumatology Annual Conference 2017.
50. Host L, Nikpour M, Calderone A, Cannell P, Roddy J. **Autologous stem cell transplantation in systemic sclerosis: a systematic review.** *Clin Exp Rheumatol* 2017 Sep-Oct; 35 Suppl. 106(4):198-207.
51. Strange G, Lau E, Giannoulatou E, Corrigan C, Kotlyar E, Kermeen F, Williams T, Celermajer D, Dwyer N, Whitford H, Wrobel J, Feenstra J, Lavender M, Whyte K, Collins N, Steele P, Proudman S, Thakkar V, Keating D, Keogh A. **Survival of idiopathic pulmonary arterial hypertension patients in the modern era in Australia and New Zealand.** *Heart, Lung and Circulation* 2017; S1443-9506.
52. Jee AS, Adelstein S, Bleasel J, Keir GJ, Nguyen M, Sahhar J, Youssef P, Corte TJ. **Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).** *J Clin Med* 2017; 6(5): 51.
53. Mejia Otero C, Assassi S, Hudson M, Mayes MD, Estrada-Y-Martin R, Pedroza C, Mills TW, Walker J, Baron M, Stevens W, Proudman SM, Nikpour M, Mehra S, Wang M, Fritzler MJ; Canadian Scleroderma Research Group; Australian Scleroderma Cohort Study; Genetics versus Environment in Scleroderma Outcome Study. **Antifibrillar Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis.** *J Rheumatol* 2017; 44(6):799-805.
54. Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman S, Williams T, Celermajer D, Sahhar J, Wong P, Thakkar V, Dwyer N, Wrobel J, Chin W, Liew D, Staples M, Buchbinder R, Nikpour M. **Multicentre randomised**

- placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol.** *BMJ Open*. Volume 6, Issue 12. December 8 2016.
55. Boulous D, Ngian G-S, Rajadurai A, Elford K, Stevens W, Proudman S, Owen C, Roddy J, Nikpour M, Youssef P, Hill C, Sahhar J. **Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.** *International Journal of Rheumatic Diseases*. 2017 Apr;20(4):481-488. doi: 10.1111/1756-185X.13035. Epub 2017 Mar 24.
56. Morrisroe K, Stevens W, Proudman S, Nikpour M. **A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults.** *International J Rheum Dis* 2017; 20(11):1728-1750
57. Esposito J, Brown Z, Stevens W, Sahhar J, Rabusa C, Zochling J, Roddy J, Walker J, Proudman S, Nikpour M. **The association of low complement with disease activity in systemic sclerosis.** *Arthritis Care Res*. 22 October 2016.
58. Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ | Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS). **Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations.** *Medicine (Baltimore)*. 2016 Aug;95(35):e4713. doi: 10.1097/MD.0000000000004713.
59. Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Prior D, Nikpour M on behalf of the Damage Index Working Group of the Scleroderma Clinical Trials Consortium. **Measures of disease status in systemic sclerosis: a systematic review.** *Arthritis & Rheumatology*. 2017 Feb;46(4):473-487. doi: 10.1016/j.semarthrit.2016.07.010. Epub 2016 Jul 29.
60. Nikpour M, Prior D, Proudman S, Stevens W. **The Australian Scleroderma Interest Group (ASIG) proposed algorithm for pulmonary arterial hypertension screening in scleroderma: more selective and judicious use of echocardiography. Invited response to letter by Ramchand J et al.** *Internal Medicine Journal*. Accepted 4th April 2016; 46(6):751-2.
61. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. **Determinants of unemployment amongst Australian systemic sclerosis patients: results from a multicentre cohort study.** *Clinical and Experimental Rheumatology*. 2016;34(5 Suppl 100):S79-84.
62. Nikpour M, Prior D, Celermajor D. **REVEAL truly reveal whether patients with pulmonary arterial hypertension should be anticoagulated?** *Circulation*. Accepted 1st March 2016.
63. Nikpour M, Prior D, Celermajor D. **Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)".** *Circulation* 2016;133(20):e661.
64. Proudman S, Nikpour M, Hudson M. **Improving care of autoimmune connective tissue diseases: Lessons from longitudinal cohorts.** *Best Pract Res Clin Rheumatol* 2016; 30(1):1-2.
65. Thakkar V, Stevens W, Prior D, Rabusa C, Sahhar J, Walker J.G., Roddy J, Lester S, Rischmueller M, Zochling J, Nash P, Gabbay E, Youssef P, Proudman SM, Nikpour M. **The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.** *Clinical and Experimental Rheumatology*. 2016 Sep-Oct;34 Suppl 100(5):129-136. Epub 2016 May 23
66. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M, The Australian Scleroderma Interest Group (ASIG). **Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicentre cohort study.** *BMC Pulmonary Medicine*. 2016 Sep 27;16:134.
67. Owen C, Ngian G-S, Moore O, Stevens W, Nikpour M, Rabusa C, Proudman S, Roddy J, Zochling J, Hill C, Sturgess A, Tymms K, Youssef P, Sahhar J. **Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis –associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.** *Clinical and Experimental Rheumatology*. 2016 Sep-Oct;34 Suppl 100(5):170-176. Epub 2016 Mar 24.
68. Morrisroe K, Frech T, Schniering J, Maurer B, Nikpour M. **Systemic sclerosis: The need for structured care.** *Best Practice & Research Clinical Rheumatology*. 2016. 30(1): 3-21.

69. Leclair V, Hudson M, Proudman S, Stevens W, Fritzler M, Wang M, Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG), Nikpour M, Baron M. **Subsets in systemic sclerosis: one size does not fit all.** *Journal of Scleroderma and Related Disorders*. 2016;1(3):298-306.
70. Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD7, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Cohort Study (ASCS); Genetics versus Environment in Scleroderma Outcome Study (GENISOS). **Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival.** *Autoimmunity*. 2015 Jul-Aug;48(8):542-51. doi: 10.3109/08916934.2015.1077231. Epub 2015 Aug 31.
71. Wodkowski M, Hudson M1, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS), Baron M1,2,3, Fritzler MJ10. **Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects.** *Clin Exp Rheumatol*. 2015 Jul-Aug;33(4 Suppl 91):S131-5. Epub 2015 Aug 27.
72. Quinlivan A, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, and Nikpour M. **Cost Savings with a New Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis.** *Intern Med J*. 2015 Nov;45:1134-40.
73. Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour M. **A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis.** *Arthritis Res Ther*. 2015 Jan 18;17:7. doi: 10.1186/s13075-015-0517-5.
74. Moore OA, Proudman SM, Goh N, Corte TJ, Rouse H, Hennessy O, Morrisroe K, Thakkar V, Sahhar J, Roddy J, Youssef P, Gabbay E, Nash P, Zochling J, Stevens W, Nikpour M. **Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.** *Clin Exp Rheumatol*. 2015 Jul-Aug;33(4 Suppl 91):S111-6. Epub 2015 Aug 5.
75. Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG. **Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.** *Arthritis Rheumatol*. 2015 Dec;67(12):3234-44. doi: 10.1002/art.39316.
This paper has attracted considerable interest:
A. Editorial Comment: Ligon CB, Wigley FM. Editorial: Scleroderma: Bringing a Disease From Black-and-White Into Technicolor. *Arthritis Rheumatol*. 2015 Dec;67(12):3101-3. doi: 10.1002/art.39310. PMID: 26245737
B. Award for Best Research Higher Degree Student Publication 2015 (Flinders University)
C. ABC news Report Sunday 6 March 2016 South Australia: <http://www.abc.net.au/news/2016-03-06/phd-student-unearths-scleroderma-clusters/7222216>
76. Papachristos D.A, Nikpour M, Hair C and Stevens W. **Intravenous cyclophosphamide as a therapeutic option for severe refractory gastric antral vascular ectasia in systemic sclerosis** *Internal Medicine Journal* 2015 Oct; 45 (10) Pages: 1077–1081,
77. Morrisroe KB, Nikpour M, Proudman SM. **Musculoskeletal Manifestations of Systemic Sclerosis.** *Rheum Dis Clin North Am*. 2015 Aug;41(3):507-18. doi: 10.1016/j.rdc.2015.04.011. Epub 2015
78. Thakkar V, Nikpour M, Stevens W, Proudman SM. **Prospects for improved screening and outcomes for patients with scleroderma-related pulmonary hypertension. Invited review.** *Intern Med J* 2015; 45(3):248-54.
79. Osthoff M, Ngian G-S, Dean M, Nikpour M, Stevens W, Proudman S, Eisen D, Sahhar J. **The Lectin Pathway of Complement - a Potential Role in the Pathogenesis and Disease Manifestations of Systemic Sclerosis.** *Arthritis Rheum* 2015;66:S751-S751.
80. Zochling J, Newell F, Charlesworth JC, Leo P, Stankovich J, Cortes A, Zhou Y, Stevens W, Sahhar J, Roddy J, Nash P, Tymms K, Rischmueller M, Lester S, Proudman S, Brown MA. **An Immunochip based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3.** *Arthritis Res Ther*. 2014;16:438.

81. Quinlivan A, Moore OA, Romas E, Nikpour M. **Whose responsibility is it to assess cardiovascular risk in patients with rheumatoid arthritis?** *Internal Medicine Journal* 2014;44(1):108-9.
82. Vacca A, Meune C, Gordon J, Chung L, Proudman S, Assassi S, Nikpour M, Rodriguez-Reyna TS, Khanna D, Lafyatis R, Matucci-Cerinic M, Distler O, Allanore Y; on behalf of the Scleroderma Clinical Trial Consortium (SCTC) Cardiac Subcommittee. **Cardiac arrhythmias and conduction defects in systemic sclerosis.** *Rheumatol (Oxford)*. 2014;53(7):1172-7.
83. Osthoff M, Ngian GS, Dean MM, Nikpour M, Stevens W, Proudman S, Eisen DP, Sahhar J. **Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study.** *Arthritis Res Ther* 2014 Nov 18;16(6):480.
84. Morrisroe KB, Stevens W, Nandurkar H, Prior D, Thakkar V, Roddy J, Zochling J, Sahhar J, Tymms K, Sturgess A, Major G, Kermeen F, Hill C, Walker J, Nash P, Gabbay E, Youssef P, Proudman S, Nikpour M. **The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis.** *Clin Exp Rheumatol* 2014;32(6):S133-S137 .
85. Ngian GS, Sahhar J, Proudman SM, , Wicks IP, Van Doornum S. **Arterial stiffness is increased in systemic sclerosis: a cross-sectional comparison with matched controls.** *Clin Exp Rheumatol* 2014;32:S-161-6.
86. Thakkar V, Moore OA, Stevens W, Nikpour M. **Performance of Screening Algorithms in Systemic Sclerosis-Related Pulmonary Arterial Hypertension: A Systematic Review.** *Int Med J*, accepted March 11, 2013.
87. Nikpour M, Stevens W, Proudman S, Buchbinder R, Prior D, Zochling J, Williams T, Gabbay E, Nandurkar H. **Should patients with scleroderma-related pulmonary arterial hypertension be anticoagulated?** *Intern Med J* 2013;43(5):599-603.
88. Moore O, Goh N, Corte T, Rouse H, Hennessy O, Byron J, Vivek Thakkar V, Sahhar J, Gabbay E, Roddy J, Youssef P, Nash P, Zochling J, Proudman S, Stevens W, Nikpour M. **Extent of Disease on High-Resolution CT Lung is a Predictor of Decline and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease.** *Rheumatology (Oxford)* 2013;52(1):155-60.
89. Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman S, Nikpour M. **The Inclusion of N-Terminal pro-Brain Natriuretic Peptide in a Sensitive Screening Strategy for Systemic Sclerosis-Related Pulmonary Arterial Hypertension: a cohort study.** *Arthritis Res Ther*. 2013;15(6):R193-1-R193-11.
90. Mandana Nikpour and Murray Baron. **Mortality in Systemic Sclerosis: lessons learned from population-based and observational cohort studies.** *Current Opinion in Rheumatology* 2013; 26(2):131-7.
91. Thakkar V, Stevens W, Prior D, Moore O, Byron J, Liew D, Patterson K, Hissaria P, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, Celermajer D, Gabbay E, Youssef P, Proudman SM, Nikpour M. **N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.** *Arthritis Res Ther* 2012;14:R143.
92. Thakkar V, Moore O, Stevens W, Nikpour M. **Managing Scleroderma: challenges in primary care.** *Medicine Today* 2012;13(6): 35-42.
93. Ngian GW, Sahhar J, Proudman SM, Stevens W, Wicks IP, Van Doornum S. **Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis.** *Annals of the Rheumatic Disease* 2012; Dec; 71 (12) 1980-3 (Epub 2012 Apr 24).
94. Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, Minson R, Hill C, Chow K, Sahhar J, Chow K, Proudman S and Nikpour M. **Predictors of Mortality in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: a cohort study.** *Arthritis Res Ther* 2012;14:R213:1-9.
95. Dalton B, McNeil K, Keogh A, Williams T, Proudman S, Gabbay E, Kotlyar E, Weintraub R, Kermeen F, Celermajer D. **Design and delivery of an e-learning curriculum for physicians involved in the management of pulmonary hypertension.** *Int J Clin Pract* 2012;66(11):1117-1124.
96. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W. **Prevalence, correlates and clinical usefulness of antibodies to RNA Polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.** *Arthritis Res Ther*. 2011;22;13(6):R211.

97. Nikpour M, Stevens WM, Herrick AL, Proudman SM. **Epidemiology of systemic sclerosis**. Best Practice & Research Clinical Rheumatology 2010; 24(6):857-69

Conference presentations – oral

1. Z Brown, D Hansen, S Proudman, W Stevens, M Nikpour **Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: a meta-analysis of long-term outcomes**. Oral Abstract at PHSANZ October 2019, Brisbane.
2. Z Brown, D Hansen, M Wilson, L McWilliams, L Spargo, J Walker, W Stevens, S Proudman, M Nikpour **Retrospective evaluation of the ASIG and DETECT algorithms for the early detection of pulmonary arterial hypertension in systemic sclerosis**. Oral Abstract at PHSANZ October 2019, Brisbane.
3. Lin E, Vincent FB, Sahhar J, Ngian GS, Kandane-Rathnayake R, Mende R, Morand E, Lang T, Harris J. **Analysis of serum interleukin (IL)-1a, IL-1b and IL-18 in patients with systemic sclerosis**. The Australian & New Zealand Society for Immunology Annual Scientific Meeting, December 2019, Adelaide, Australia. *Selected for oral presentation in best published research session*.
4. Morrisroe K, Huq M, Rabusa C, Zochling J, Sahhar J, Roddy J, Proudman S, Stevens W, Nikpour M. **Survival in scleroderma pulmonary arterial hypertension in the modern treatment era: results from large multicentre cohort study**. October 2016 Pulmonary Arterial Hypertension Society ANZ (Melbourne). Winner Best Oral Presentation.
5. Morrisroe K, Huq M, Rabusa C, Zochling J, Sahhar J, Roddy J, Proudman S, Stevens W, Nikpour M. **Survival in scleroderma pulmonary arterial hypertension in the modern treatment era: results from large multicentre cohort study**. ARA-RHPA Conference May 2016, Darwin, Australia.
6. Ferdowsi N, Huq M, Burchell J, Mancuso S, Tay T, Stevens W, Rabusa C, Hudson M, Sundararajan V, Prior D, Proudman S, Baron M, Nikpour M. **Development of a disease damage index in systemic sclerosis using consensus and data driven methods**. ARA-RHPA Conference May 2016, Darwin, Australia.
7. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. **Determinants of unemployment amongst Australian systemic sclerosis patients: results from a multicentre cohort study**. Journal of Scleroderma and Related Disorders 2016 Abstract CO-31 1 (1) Pages: 35 – 36
8. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. **Survival in Systemic Sclerosis (SSc)-related Pulmonary Arterial Hypertension (PAH) in the Modern Treatment Era..** Journal of Scleroderma and Related Disorders 2016 Abstract P.083 1 (1) Pages: 68 – 68
9. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. **Risk Factors for Development of Pulmonary Arterial Hypertension (PAH) in Australian Scleroderma (SSc) Patients: Results from a Large Multicenter Cohort Study**. Journal of Scleroderma and Related Disorders 2016 Abstract P.083 1 (1) Pages: 69 – 69
10. Ferdowsi N, Huq M, Burchell JL, Mancuso S, Tay T, Stevens W, Rabusa C, Hudson M, Sundararajan V, Prior D, Proudman S, Baron M, Nikpour M. **Development of a Disease Damage Index in Systemic Sclerosis: survey of experts, item reduction and item weighting using consensus and data driven methods**. Journal of Scleroderma and Related Disorders 2016 Abstract CO-42 1 (1) Pages: 39 – 39
11. Esposito J, Stevens W, Rabusa C, Sahhar J, Walker J, Thakkar V, Major G, Roddy J, Zochling J, Proudman S, Nikpour M. **The Association of Hypocomplementemia with disease activity in systemic sclerosis**. ARA-RHPA ASM Adelaide, 2015. Intern Med J, Supp S2, May 2015
12. Nguyen L, Lester S, Proudman S, Hill C, Rischmueller eaM and Australian Scleroderma Interest Group (ASIG) study investigators. **Fc gamma receptor IIIB gene copy number variation in systemic sclerosis**. Oral presentation at the SA Branch of the Rheumatology Association's annual meeting 23rd October 2015. *Won the Philip Alpers Award for the Best Scientific Presentation*.
13. Morrisroe K, et al. **Predictors of pulmonary arterial hypertension in Australian scleroderma patients: results from a large multicentre cohort study**. October 2015 Pulmonary Arterial Hypertension Society ANZ (Sydney)
14. Quinlivan A, Thakkar V, Stevens W, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash N, Lester S, Rischmueller M, Proudman SM, Nikpour M. **Cost savings with a biomarker-based screening**

- algorithm for pulmonary arterial hypertension in systemic sclerosis.** ARA-RHPA Annual Scientific Meeting, Hobart, 2014. *Intern Med J* 2014;44:5-5. (**Helen Moran Award, Arthritis Australia**)
15. Lester S, Patterson K, Walker J, Charlesworth J, Stankovich J, Stevens W, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Rischmueller M, Proudman S, Brown M, Zochling J. **Associations Between HLA DRB1 Alleles And Autoantibodies In Systemic Sclerosis.** ARA-RHPA ASM Hobart, 2014. *Intern Med J* 2014;44:2-2.
 16. Tay T, Stevens W, Baron M, Hudson M, Rabusa C, Prior D, Proudman S, Nikpour M. **Early accrual of organ damage in scleroderma: rationale for derivation and validation of a disease damage index in systemic sclerosis.** 3rd Systemic Sclerosis World Congress, Rome, 2014. *Clin Exp Rheumatol*, 2014; 32(2):S-6
 17. Hao YJ, Thakkar V, Stevens W, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash N, Lester S, Rischmueller M, Proudman SM, Nikpour M. **A comparison of the predictive accuracy of three screening models (DETECT v. ESC/ERS v. ASIG) for pulmonary arterial hypertension in systemic sclerosis.** 3rd Systemic Sclerosis World Congress, Rome, 2014. *Clin Exp Rheumatol*, 2014; 32(2):S20-S21.
 18. Nikpour M, Proudman S, Zochling J, Sahhar J, Nash P, Youssef P, Major G, Roddy J, Thakkar V, Walker J, Stevens W. **Early mortality in systemic sclerosis: rationale for forming a multinational inception cohort of patients with scleroderma (the INSYNc) study.** ARA-RHPA Annual Scientific Meeting, Perth, 2013. *Int Med J* 2013: 43:4-4.
 19. Charlesworth J, Stankovich J, Lewis P, Byron J, Stevens W, Sahhar J, Proudman S, Roddy J, Nash P, Tymms K, Rischmeueller M, Lester S, Brown M, Zochling J. **An immunochip based interrogation of scleroderma susceptibility variants.**
 - 2nd Systemic Sclerosis World Congress, Madrid, Spain, 2012. *Rheumatology (Oxford)* 2012; 51: 15-16.
 - ARA-RHPA ASM Canberra, 2012. *Int Med J* 2012;42:2-2
 20. Moore O, Goh N, Corte T, Rouse H, Hennessy O, Byron J, Thakkar V, Sahhar J, Roddy J, Youssef P, Nash P, Zochling J, Proudman S, Stevens W, Nikpour M. **Extent of Lung Disease on High-Resolution CT Lung is a Predictor of Mortality in Systemic Sclerosis-Related Interstitial Lung Disease.** 2nd Systemic Sclerosis World Congress, Madrid, Spain, 2012. *Rheumatology (Oxford)* 2012; 51:3-4.
 21. Moore O, Goh N, Corte T, Rouse H, Hennessy O, Byron J, Thakkar V, Sahhar J, Roddy J, Youssef P, Nash P, Zochling J, Proudman S, Stevens W, Nikpour M. **Identifying and Quantifying Prognostic Factors in Systemic Sclerosis-Related Interstitial Lung Disease Using a Time-Varying Covariate Survival Model.** 2nd Systemic Sclerosis World Congress, Madrid, Spain, 2012. *Rheumatology (Oxford)* 2012; 51:3-3.
 22. Ngian GS, Stevens W, Byron J, Tran A, Roddy J, Minson R, Hill C, Chow K, Sahhar J, Proudman S, Nikpour M. **Survival and Predictors of Mortality in Australian Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.** American College of Rheumatology Annual Scientific Meeting, Chicago, 2011. *Arthritis Rheum* 2011.
 23. Stevens W, Byron J, Nash P, Zochling J, Gabbay E, Chan M, Youssef P, Sahhar J, Tymms K, Sturgess A, Celermajer D, Nikpour M, Proudman S. **Pulmonary arterial hypertension in an Australian systemic sclerosis cohort.** 1st Systemic Sclerosis World Congress, Florence, Italy, 2010. *Clin Exp Rheumatol (Scleroderma Care and Research)* 2010;S.02B.02:6.
 24. Nikpour M, Micallef M, Byron J, Hissaria P, Paspaliaris W, Sahhar J, Proudman S, Stevens W. **Prevalence and correlates of antibodies to RNA polymerase III in systemic sclerosis.** 1st Systemic Sclerosis World Congress, Florence, Italy, 2010. *Clin Exp Rheumatol (Scleroderma Care and Research)* 2010;S.05.02:12.
 25. Stevens W, Zochling J, Chan M, Tymms K, Gabbay E, Sahhar J, Sturgess A, Hill C, Youssef P, Nash P, Proudman S. **Screening for pulmonary hypertension and interstitial lung disease in systemic sclerosis using the Australian Scleroderma Screening Programme (ASSP) database.** ARA-RHPA Annual Scientific Meeting, New Zealand, 2009. *Intern Med J* 2009;39 (Suppl 2); A35.
 26. Hissaria P, Byron J, Sahhar J, Cassidy J, Paspaliaris W, Stevens W, Proudman S. **Clinical significance of anti RNA polymerase III antibodies in a cohort of scleroderma patients from ASIG registry.** ARA-RHPA Annual Scientific Meeting, New Zealand, 2009. *Intern Med J* 2009;39 (Suppl 2); C28.

Conference presentations – posters

1. Z Brown, D Hansen, M Wilson, J Roddy, G-S Ngian, J Sahhar, K Morrisroe, J Walker, S Proudman, W Stevens, M Nikpour. **Retrospective application of the ESC/ERS risk prediction model in scleroderma (SSc) patients with newly diagnosed pulmonary arterial hypertension (PAH) at baseline and follow-up.** *Poster Presentation at PHSANZ October 2019, Brisbane.*
2. Fairley J, Hansen D, Proudman S, Sahhar J, Ngian G-S, Walker J, Strickland G, Wilson M, Morrisroe K, Ferdowsi N, Major G, Roddy J, Stevens W, Nikpour M. **Clinical characteristics and survival in systemic sclerosis-mixed connective tissue disease and systemic sclerosis-overlap syndrome.** ACR, Nov 2019, Atlanta, USA.
3. Abbot S, McWilliams L, Spargo L, de Costa C, Ur-Rehman Z, Proudman S, Bossingham D. **Systemic sclerosis in Cairns: an epidemiological study.** APLAR-ARA, April 2019, Brisbane Australia.
4. Habib P, Roddy J, Keen H, Raymond W. **Role of Ultrasound in Skin and End-Organ Disease in Scleroderma.** APLAR-ARA, April 2019, Brisbane Australia.
5. Khadra, Y, Jenny Walker et al. **Scleroderma renal crisis: observations from the South Australian scleroderma register (SASR).** APLAR-ARA, April 2019, Brisbane Australia.
6. Moxey J, Huq M, Proudman S, Sahhar J, Ngian G-S, Walker J, Strickland G, Wilson M, Ross L, Major G, Roddy J, Stevens W, Nikpour M. **Significance of Anti-Neutrophil Cytoplasmic Antibodies in Systemic Sclerosis.** ACR, Oct 2018, Chicago, USA.
7. Ross LJ, Patel S, Stevens W, Wilson M, Ferdowsi N, Strickland G, Proudman S, Burns A, Prior D, Nikpour M. **Echocardiography in the Detection of Primary Systemic Sclerosis Heart Involvement.** ACMD Research Week St Vincent's Hospital, May 2018, Melbourne, Australia.
8. Lin E, Vincent F, Harris J, Kandane-Rathnayake R, Ngian G-S, Sahhar J, Morand E, Lang T. **Serum levels of macrophage migration inhibitory factor and Interleukin-1 family cytokines are elevated in Systemic Sclerosis.** EULAR ASM June 2018, Amsterdam, Netherlands.
9. Lin E, Vincent F, Harris J, Kandane-Rathnayake R, Ngian G-S, Sahhar J, Morand E, Lang T. **Serum levels of macrophage migration inhibitory factor and Interleukin-1 family cytokines are elevated in Systemic Sclerosis.** ARA-RHPA Conference May 2018, Melbourne, Australia.
10. Ross LJ, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Walker J, Sahhar J, Ngian GS, Zochling J, Roddy J, Tymms K, Major G, Strickland G, Proudman S, Nikpour M. **The Role of Inflammatory Markers in Assessment of Disease Activity in Systemic Sclerosis.** ARA-RHPA Conference May 2018, Melbourne, Australia.
11. Ross LJ, Patel S, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Strickland G, Proudman S, Prior D, Nikpour M. **Echocardiography in Detection of Primary Systemic Sclerosis Cardiac Disease.** ARA-RHPA Conference May 2018, Melbourne, Australia.
12. Ross LJ, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Walker J, Sahhar J, Ngian GS, Zochling J, Roddy J, Tymms K, Major G, Strickland G, Proudman S, Nikpour. **The Role of Inflammatory Markers in Assessment of Disease Activity in Systemic Sclerosis.** World Scleroderma Congress Conference, Bordeaux, France, February 2018.
13. Ross LJ, Patel S, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Strickland G, Proudman S, Prior D, Nikpour M. **Echocardiography in Detection of Primary Systemic Sclerosis Cardiac Disease.** World Scleroderma Congress Conference February 2018, Bordeaux, France.
14. Morrisroe K, Stevens W, Rabusa C, Sahhar J, Ngian GS, Ferdowsi N, Hill C, Proudman S, Nikpour M. **Quantifying the Burden of Systemic Sclerosis in Australia: a Data Linkage Study.** World Scleroderma Congress Conference February 2018, Bordeaux, France.
15. Morrisroe K, Hudson M, Baron M, de Vries-Bowstra J, Carreira P, Wuttge DM, Wang M, Frech T, Stevens W, Proudman SM, Nikpour M. **Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort.** World Scleroderma Congress Conference February 2018, Bordeaux, France.
16. Morrisroe K, Huq M, Rabusa C, Zochling J, Sahhar J, Roddy J, Proudman S, Stevens W, Nikpour M. **Survival in scleroderma pulmonary arterial hypertension in the modern treatment era: results from large multicentre cohort study.** American College of Rheumatology Annual Scientific Meeting, Washington DC, 2016.

17. Morrisroe K, Sudararajan V, Stevens W, Sahhar J, Zochling J, Roddy J, Proudman S, Nikpour M, Australian Scleroderma Interest Group (ASIG). **Work Productivity in Systemic Sclerosis and association with Health-Related Quality of Life.** American College of Rheumatology Annual Scientific Meeting, Washington DC, 2016.
18. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. **Determinants of Unemployment Amongst Australian Systemic Sclerosis Patients: Results from a Multicentre Cohort Study.** ARA-RHPA Conference May 2016, Darwin, Australia.
19. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. **Risk Factors for Development of Pulmonary Arterial Hypertension (PAH) in Australian Scleroderma (SSc) Patients: Results from a Large Multicenter Cohort Study.** ARA-RHPA Conference May 2016, Darwin, Australia.
20. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. **Survival in scleroderma pulmonary arterial hypertension in the modern treatment era: results from large multicentre cohort study.** February 2016 Scleroderma Congress Conference (Lisbon, Portugal)
21. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. **'Risk factors for the development of pulmonary arterial hypertension in Australian scleroderma patients: results from a large multicentre cohort study.** February 2016 Scleroderma Congress Conference (Lisbon, Portugal)
22. Ferdowsi N, Huq M, Burchell JL, Mancuso S, Tay T, Stevens W, Rabusa C, Hudson M, Sundararajan V, Prior D, Proudman S, Baron M, Nikpour M. **Development of a Disease Damage Index in Systemic Sclerosis: survey of experts, item reduction and item weighting using consensus and data driven methods.** ACR ASM, San Francisco, 2015. *Arthritis Rheumatol.* 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/development-of-a-disease-damage-index-in-systemic-sclerosis-using-consensus-and-data-driven-methods/>.
23. Hudson M, Baron M, Wang M, Canadian Scleroderma Research Group, Australian Scleroderma Cohort Study, Proudman S, Nikpour M, Rabusa C, Stevens W. **Health-Related Quality of Life in Early Systemic Sclerosis.** ACR ASM, San Francisco, 2015. *Arthritis Rheumatol.* 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/health-related-quality-of-life-in-early-systemic-sclerosis/>.
24. A.Rajadurai, G.S. Ngian, K. Elford, W. Stevens, S. Proudman, J. Roddy, M. Nikpour, P. Youssef, C. Hill, J. Sahhar. **Mycophenolate mofetil in the treatment of scleroderma-associated diffuse skin disease: Results from the Australian Scleroderma Cohort Study.** ARA-RHPA ASM Adelaide, 2015. *Intern Med J, Supp S2, May 2015*
25. Proudman S, Nikpour M, Stevens W. **Changes in Rheumatologists' Screening Practices for Pulmonary Arterial Hypertension and Interstitial Lung Disease.** ARA-RHPA ASM Adelaide, 2015. *Intern Med J, Supp S2, May 2015*
26. Murthy S, Lester S, Limaye V, Goldblatt F, McWilliams L, Nikpour M, Stevens W, Zochling J, Proudman S. **Validation of the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis in Australian patients.** ARA-RHPA ASM Adelaide, 2015. *Intern Med J, Supp S2, May 2015*
27. Ferdowsi N, Tay T, Baron M, Stevens W, Hudson M, Sundararajan V, Mancuso S, Burchell J, Rabusa C, Prior D, Proudman S, Nikpour M. **Development of a Disease Damage Index in Systemic Sclerosis: Survey of experts and item reduction using Rasch Modelling.** ARA-RHPA ASM Adelaide, 2015. *Intern Med J, Supp S2, May 2015*
28. Hissaria P, Bert A, Proudman S, Goodall G, Khew-Goodall Y. **Differential Pattern of MiroRNA expression in limited and diffuse cutaneous variants of Systemic Sclerosis – a possible mechanism to explain the unique clinical phenotypes.** ARA-RHPA ASM Adelaide, 2015. *Intern Med J, Supp S2, May 2015*
29. Tay T, Ferdowsi N, Stevens W, Hudson M, Baron M, Rabusa C, Prior D, Proudman S, Nikpour M. **Measures of Disease Status in Systemic Sclerosis: Systematic Review.**
 - American College of Rheumatology ASM, Boston, 2014. *Arthritis Rheum* 2014;66:S314-S314.
 - ARA-RHPA ASM Adelaide, 2015. *Intern Med J, Supp S2, May 2015*
30. Hao Y, Hudson M, Carreira P, Stevens W, Rabusa C, Tatibouet S, Carmona L, Joven BE, Proudman S, Baron M, Nikpour M. **Early Mortality in Australian, Canadian and Spanish Scleroderma patients: Rationale for establishing a multi-national inception cohort of patients with systemic sclerosis.** American College of Rheumatology ASM Boston, 2014. *Arthritis Rheum* 2014; 66:S316-S316.
31. Michael Osthoff, Gene-Siew Ngian, Melinda M Dean, Mandana Nikpour, Wendy Stevens, Susanna Proudman, Damon P Eisen and Joanne Sahhar. **Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study.** ARA-RHPA ASM Hobart, 2014. *Intern Med J, Supp 80, May 2014*

32. Owen C, Ngian G, Elford K, Moore O, Nikpour M, Stevens W, Proudman S, Roddy J, Zochling J, Hill C, Nash P, Sturgess A, Sahhar J. **Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study.**
 - American College of Rheumatology ASM Boston, 2014. *Arthritis Rheum* 2014;66:S740-S741.
 - ARA-RHPA ASM Hobart, 2014. *Intern Med J* 2014;44:
33. Patterson K, Roberts-Thomson P, Lester S, Proudman S, Rischmueller M, Stevens W, Mandana N, Zochling J, Sahhar J, Nash P, Rodd J, Hill C, Walker J. **Autoantibody Associations Among A Well-Characterized Australian Systemic Sclerosis (Ssc) Cohort.** ARA-RHPA ASM Hobart, 2014. *Intern Med J* 2014;44:35-35.
34. Foreman C, Sahhar J, Ngian G, Briggs N, Spargo L, Kathleen E, McWilliams L, Proudman S. **Vitamin D In Systemic Sclerosis (SSc): Prevalence And Associations Of Vitamin D Deficiency In Patients From Two Centres Of The Australian Scleroderma Cohort Study (ASCS).** ARA-RHPA ASM Hobart, 2014. *Intern Med J* 2014;44:35-35.44:33-33.
35. Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash N, Lester S, Hill C, Rischmueller M, Proudman SM, Nikpour M. **A comparison of the predictive accuracy of three screening models (DETECT v. ESC/ERS v. ASIG) for pulmonary arterial hypertension in systemic sclerosis.** ARA-RHPA ASM Hobart, 2014. *Intern Med J* 2014;44:23-23. (*Best basic science poster ARA ASM Hobart 2014.*)
36. Hao YJ, Thakkar V, Stevens W, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman S, Nikpour M. **A comparison of the predictive accuracy of three screening models (DETECT v. ESC/ERS v. ASIG) for pulmonary arterial hypertension in systemic sclerosis.** 3rd Systemic Sclerosis World Congress, Rome 2014. *Clin Exp Rheumatol* 2014; 32(2):S20-S21
37. Tay T, Stevens W, Baron M, Hudson M, Rabusa C, Prior D, Proudman S, Nikpour M. **Early accrual of organ damage in scleroderma: rationale for derivation and validation of a disease damage index in systemic sclerosis.** 3rd Systemic Sclerosis World Congress, Rome 2014. *Clin Exp Rheumatol* 2014; 32(2):S31-S31.
38. Quinlivan A, Thakkar V, Stevens W, Prior P, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash P, Lester S, Hill C, Rischmueller M, Proudman S, Nikpour M. **Cost savings with a biomarker-based screening algorithm for pulmonary arterial hypertension in systemic sclerosis.** 3rd Systemic Sclerosis World Congress, Rome, 2014; *Clin Exp Rheumatol* 2014; 32(2):S31-S31.
39. Nikpour M, Hudson M, Stevens W, Rabusa C, Tatibouet S, Proudman S, Baron M. **Early mortality in Australian and Canadian scleroderma patients: Rationale for Establishing a Multinational Inception Cohort of Patient with Systemic Sclerosis.** 3rd Systemic Sclerosis World Congress, Rome 2014; *Clin Exp Rheumatol* 2014;32(2):S36-S36. (*Prize winning abstract*)
40. Thakkar V, Stevens W, Prior D, Sahhar J, Roddy JE, Zochling J, Nash P, Youssef P, Proudman S, Nikpour M. **Asymmetric Dimethylarginine Levels In The Early Detection Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension.** American College of Rheumatology ASM San Diego, 2013. *Arthritis Rheum* 2013; 65: S775-S775.
41. Moore O, Proudman S, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Sahhar J, Roddy JE, Youssef P, Gabbay E, Nash P, Zochling J, Stevens W, Nikpour M. **Quantifying Change In Pulmonary Function As a Prognostic Marker In Systemic Sclerosis-Related Interstitial Lung Disease.** American College of Rheumatology ASM San Diego, 2013. *Arthritis Rheum* 2013;65:S289-S289.
42. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Byron V, Sahhar J, Roddy J, Youssef P, Nash P, Zochling J, Proudman SM, Stevens W, Nikpour M and Australian Scleroderma Interest Group. **Identifying and quantifying prognostic factors in systemic sclerosis-related interstitial lung disease using a time-varying covariate survival model.** EULAR ASM Madrid 2013 *Ann Rheum Dis* 2013;71:Suppl 3 234-235
43. Thakkar V, Stevens W, Prior D, Moore O, Byron J, Patterson K, Hissaria P, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, Celermajer D, Gabbay E, Youssef P, Proudman S, Nikpour M and Australian Scleroderma Interest Group. **N-Terminal Pro-Brain Natriuretic Peptide In A Madrid Algorithm For Pulmonary Arterial Hypertension In Systemic Sclerosis.** EULAR ASM 2013. *Ann Rheum Dis* 2013;72 (Suppl 3):242-242.
44. Nikpour M, Baron M, Hudson M, Carreira P, Hunzelmann N, Frech T, Sahhar J, Nash P, Roddy J, Schrieber L, Stevens W, Proudman S and Australian Scleroderma Interest Group. **Early Accrual Of Organ Damage In Systemic Sclerosis: Rationale For Forming A Multinational Inception Cohort Of Patients With Scleroderma (The Insync Study).** EULAR ASM Madrid 2013 *Ann Rheum Dis* 2013;72:649-649.

45. Nikpour M, Baron M, Hudson M, Carreira P, Hunzelmann N, Frech T, Sahhar J, Nash P, Major G, Youssef P, Roddy J, Zochling J, Proudman S, Stevens W. **Early Mortality In Systemic Sclerosis: Rationale For Forming A Multinational Inception Cohort Of Patients With Scleroderma (The Insync Study).** EULAR ASM Madrid 2013 *Ann Rheum Dis* 2013;72:499-499.
46. Nikpour M, Stevens W, Roddy J, Zochling J, Sahhar J, Walker J, Thakkar V, Nash P, Youssef P, Tymms K, Schrieber L, Zochling J, Stevens W, Proudman S. **Early accrual of organ damage in systemic sclerosis: rationale for forming a multinational inception cohort of patients with scleroderma (the INSINC study).** ARA-RPHA Annual Scientific Meeting, Perth 2013. *Int Med J* 2013;43:19-19.
47. Thakkar V, Stevens W, Prior D, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, Youssef P, Proudman S, Nikpour M. **Assymetric Dimethylarginine (Adma) Levels In The Early Detection Of Systemic Sclerosis Related Pulmonary Arterial Hypertension (Ssc-Pah).** ARA-RPHA Annual Scientific Meeting, Perth 2013. *Int Med J* 2013;43:19-19
48. Chaudhary SH, Proudman S, Limaye VS. **Idiopathic Inflammatory Myositis Is Associated with an Increased Incidence of Systemic Sclerosis.** American College of Rheumatology ASM Washington, 2012. *Arthritis Rheum* 2012; 64:S88-S88.
49. Morrisroe KB, Stevens WM, Byron J, Thakkar V, Moore O, Proudman S, Nikpour M and Australian Scleroderma Interest Group. **Anti-Phospholipid Antibodies In Systemic Sclerosis: Prevalence And Clinical Correlations.**
 - EULAR ASM Madrid 2013. *Ann Rheum Dis* 2013;71 (Suppl 3):402-402.
 - ARA-RPHA ASM Canberra, 2012. *Int Med J* 2012;42:22-22.
50. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Byron J, Sahhar J, Roddy J, Gabbay E, Youssef P, Nash P, Zochling J, Proudman S, Stevens W, Nikpour M and Australian Scleroderma Interest Group. **Extent Of Disease On High-Resolution CT Lung Is A Predictor Of Decline And Mortality In Systemic Sclerosis-Related Interstitial Lung Disease.**
 - EULAR ASM Madrid 2013 *Ann Rheum Dis* 2013;71 (Suppl 3):396.
 - ARA-RPHA ASM Canberra, 2012. *Int Med J* 2012;42
51. Tan J, Patterson K, Proudman S, Hakendorf P, Roberts-Thomson P, Walker J. **Prevalence And Clinical Phenotypic Associations Of Anti-Ro52/Trim21 In An Australian Scleroderma Cohort.** ARA-RPHA ASM Canberra, 2012. *Int Med J* 2012;42:22-23.
52. Charlesworth J, Stankovich J, Lewis P, Byron J, Stevens W, Sahhar J, Proudman S, Roddy J, Nash P, Tymms K, Rischmueller M, Lester S, Brown M, Proudman S, Zochling J. **An Immunochip Based Interrogation Of Scleroderma Susceptibility Variants.**
 - *EULAR ASM Berlin 2012. Ann Rheum Dis* 2012;71:155-155.
53. Thakkar V, Patterson K, Stevens W, Byron J, Moore O, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, Youssef P, Proudman S, Hissaria P, Nikpour M. **Serum ICAM-1 Levels Are Related To The Presence Of Interstitial Lung Disease In Systemic Sclerosis.**
 - 2nd Systemic Sclerosis World Congress, Madrid, Spain, 2012. *Rheumatology (Oxford)* 2012; 51:29-29
 - ARA-RPHA ASM Canberra, 2012. *Int J Med* 2012;42:
54. Thakkar V, Stevens W, Prior D, Moore O, Byron J, Patterson K, Hissaria P, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, Youssef P, Proudman S, Nikpour M. **N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) Levels Predict Incident Pulmonary Arterial Hypertension in Systemic Sclerosis (SSc).**
 - 2nd Systemic Sclerosis World Congress, Madrid, Spain, 2012. *Rheumatology (Oxford)* 2012; 51:8-8
 - ARA-RPHA ASM Canberra, 2012. *Int Med J* 2012;42:6-6
55. Thakkar V, Patterson K, Stevens W, Byron J, Moore O, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, Nash P, Youssef P, Proudman P, Nikpour M, Hissaria P. **Novel Biomarkers of Dysregulated Angiogenesis Are Not Specific to Pulmonary Arterial Hypertension in Systemic Sclerosis.**
 - 2nd Systemic Sclerosis World Congress, Madrid, Spain, 2012. *Rheumatology (Oxford)* 2012; 51:28-28
 - ARA-RPHA ASM Canberra, 2012. *Int Med J* 2012;42:21-22.
56. Stevens W, Thakkar V, Moore O, Byron J, Proudman S, Zochling J, Roddy J, Sahhar J, Nash P, Youssef P, Major G, Tymms K, Hill C, Sturgess A, Schrieber L, Nikpour M. **Lung disease is the major cause of death in the Australian Systemic Sclerosis Cohort study.** 2nd Systemic Sclerosis World Congress, Madrid, Spain, 2012. *Rheumatology (Oxford)* 2012; 51:58-59.

57. W. Stevens, M. Nikpour, J. Byron, J. Roddy, J. Zochling, J. Sahhar, P. Nash, P. Youssef, K. Tymms, A. Sturgess, G. Major, S. Proudman. **Frequency, clinical characteristics and risk factors for digital ulcers in systemic sclerosis.** Presented at:
- EULAR London, 2011. *Ann Rheum Dis* 2011;70(Suppl3):669.
 - ARA-RPHA ASM, Brisbane 2011. *Int Med J* 2011:41 (Suppl 1); p 13.
58. M. Nikpour, S. Proudman, J. Roddy, J. Byron, P. Nash, J. Sahhar, P. Youssef, J. Zochling, K. Tymms, C. Hill, W. Stevens, **Mortality and causes of death in an Australian systemic sclerosis cohort.** Presented at:
- EULAR London, 2011. *Ann Rheum Dis* 2011;70(Suppl3):668.
 - ARA-RPHA Annual Scientific Meeting, Brisbane May 2011. *Int Med J* 2011:41 (Suppl 1); p 12.
59. Ngian G, Sahhar J, Byron J, Proudman S, Hill C, Roddy J, Youssef P, Tymms K, Schrieber L, Wendy S, Zochling J, Nash P, Sturgess A, Major G, Wicks I, Van Doornum S. **Prevalence of coronary heart disease in a cohort of Australian scleroderma patients.** Presented at:
- ARA-RPHA ASM, Brisbane 2011. *Int Med J*, 2011:41 (Suppl 1); p 11.
 - ACR ASM, Atlanta, Georgia, 2010. *Arthritis Rheum* 2010:62 (Suppl) S243.
 - ACR ASM, Philadelphia, 2009. *Arthritis Rheum* 2009:60 (Suppl 10) S644.
60. Ngian G, Nikpour M, Byron J, Tran A, Roddy J, Minson R, Hill C, Chow K, Sahhar J, Stevens W, Proudman S. **Survival in Australian patients with connective tissue disease-associated pulmonary arterial hypertension.** ARA-RPHA ASM, Brisbane, 2011. *Int Med J*, 2011:41 (Suppl 1); p12.
61. Jayaweera S, Sahhar J, Englert H, Proudman S, Hill C, Youssef P. **Mycophenolate Mofetil (MMF) in Scleroderma (SSc) associated Interstitial Lung Disease (ILD) and Skin Disease - The Australian Experience.** ARA-RPHA ASM, Brisbane, 2011. *Int Med J*, 2011:41 (Suppl 1); p11.
62. Stevens WMR, Zochling J, Youssef P, Nash PT, Sahhar JM, Chan MT, Tymms K, Sturgess A, Byron J, Hill C, Schreiber L, Nikpour MN, Proudman SM. **Prevalence and clinical characteristics of pulmonary arterial hypertension in systemic sclerosis using data from the Australian Scleroderma Screening Project (ASSP).** ARA-RPHA ASM, Melbourne, 2010. *Int Med J* 2010:40 (Suppl 3); p29.
63. Nikpour M, Micallef M, Byron J, Hissaria P, Paspaliaris W, Sahhar J, Proudman S, Stevens W. **Prevalence and correlates of antibodies to RNA polymerase III in systemic sclerosis.** Presented at:
- ARA-RPHA ASM, Melbourne, 2010. *Int Med J*, 2010:40 (Suppl 3); p24.
 - ACR ASM, Philadelphia, 2009. *Arthritis Rheum* 2009:60 (Suppl 10) S644.
64. Nikpour M, Byron J, Zochling J, Chan M, Nash P, Sahhar J, Sturgess A, Tymms K, Youssef P, Proudman S, Stevens W. **Describing organ damage in systemic sclerosis.** Presented at:
- ARA-RPHA ASM, Melbourne, 2010. *Int Med J*, 2010:40 (Suppl 3); p24.
 - 1st Systemic Sclerosis World Congress, Florence, Italy, 2010. *Clin Exp Rheumatol (Scleroderma Care and Research)* 2010;SP.01.61:43.
65. Zochling J, Lewis T, Byron J, Langsford D, Walsh J, Dwyer N, Kilpatrick D. **The epidemiology of scleroderma and secondary pulmonary hypertension in Tasmania.** 1st Systemic Sclerosis World Congress, Florence, Italy, February, 2010. *Clin Exp Rheumatol (Scleroderma Care and Research)* 2010.
66. SM Proudman, J Byron, J Zochling, PP Youssef, P T Nash, K Tymms, MT Chan, A Sturgess, L Schreiber, CL Hill, DS Celermajer, JM Sahhar, WM Stevens. **An on-line screening tool for cardiopulmonary complications of scleroderma - the Australian Scleroderma Screening Program.** ACR ASM, Philadelphia, 2009. *Arthritis Rheum* 2009:60 (Suppl 10) S641.
67. Padang R, Byron J, Stevens W, Kermeen F, Zochling J, Tymms K, Gabbay E, Sturgess A, Hill C, Proudman S, Celermajer D. **Prevalence of pulmonary arterial hypertension in scleroderma – results from the Australian scleroderma interest group.** Cardiac Society of Australia and New Zealand ASM Sydney, 2009. *Heart, Lung and Circulation*. 2009;18 (S 3), P S282.
68. Youssef P, Nash P, Byron J, Sahhar J, Zochling J, Tymms K, Chan M, Sturgess A, Hill C, Celermajer D, Kermeen K, Gabbay E, Proudman S, Stevens W. **Screening for pulmonary hypertension and interstitial lung disease in systemic sclerosis using the Australian Scleroderma screening program (ASSP) database.** EULAR Congress, Copenhagen Denmark, 2009. *Ann Rheum Dis* 2009;68(Suppl3):614.
69. Zochling J, Byron J, Lewis P, Dwyer N, Kilpatrick D. **High incidence of pulmonary hypertension in scleroderma patients in Tasmania.** EULAR Congress, Copenhagen Denmark, 2009. *Ann Rheum Dis* 2009;68(Suppl3):748

70. J Zochling, P Lewis, P Morley, J Byron, W Stephens, N Dwyer, D Kilpatrick. **Scleroderma: The Tassie experience.** ARA-RPHA ASM, New Zealand May 2009. *Int Med J* 2009;39 (Suppl 2); P31.
71. Stevens W, Byron J, Zochling J, Tymms K, Gabbay E, Sturgess A, Hill C, Youssef P, Nash P, Sahhar J, Chan M, Kermeen F, Proudman S. **Assessment of cardiopulmonary complications of systemic sclerosis using the Australian Scleroderma screening program (ASSP) database.** Thoracic Society of Australia and New Zealand ASM Darwin, 2009. *Respirology*, 2009;14 (S1):A69.
72. Mageswaren E, Byron J, Proudman S, Gabbay E, Phung S, Roddy J, Youssef P, Nash P, Sahhar J. **Systemic Sclerosis in Australia: using the Australian Scleroderma Screening Programme (ASSP) database to assist in assessment of cardiopulmonary complications.** ARA-RPHA ASM, Adelaide, 2008. *Int Med J*. 2008;38 (Suppl 2); A16.

State Presentations and Posters

1. Murphy S, Lester S, Limaye V, Goldblatt F, McWilliams L, Nikpour M, Stevens W, Zochling J, Proudman SM. **Validation of the 2013 ACR/EULAR classification criteria for systemic sclerosis in Australian patients.** Oral presentation at the SA branch of the ARA ASM October 2014.
2. Caroline CS, McWilliams L, Spargo L, O'Loughlin P, Ngian G, Sahhar J, Proudman SM. **Vitamin D in patients with systemic sclerosis.**
 - Oral presentation at the SA branch of the ARA ASM October 2013. **State ARA award for best clinical presentation.**
 - Oral presentation at SA RACP Advanced Trainee presentation 2014. **Taverner Award for best presentation**
3. Maree Micallef, Jill Byron, William Paspaliaris, Susanna Proudman, Jo Sahhar, Pravin Hissaria, Wendy Stevens, Mandy Nikpour. **Prevalence and Correlates of Antibodies to RNA Polymerase III in Systemic Sclerosis.** Oral presentation at St Vincent's Research Week, August 2009. **Awarded Best Junior Investigator.**
4. Sahhar J, Hissaria P, Byron, , Stevens W, , Paspaliaris W, Proudman S. **Anti-RNA polymerase III in Scleroderma.** Oral presentation to the Victorian Diagnostic Immunology Discussion Group. April 2009.
5. Hissaria P, Byron J, Sahhar J, Cassidy J, Paspaliaris W , Stevens W, Proudman S. **Clinical significance of anti RNA polymerase III antibodies in a cohort of scleroderma patients from ASIG registry.** St George's Autoantibody seminar, Nov 2008
6. Byron J, Stevens W, Proudman S, Sahhar J, Whitehead S. **A web based decision support tool and database for treatment and research into a rare, chronic disease: the Australian Scleroderma Screening Program database.** Poster presented at St Vincent's Health Research Week 25-27 August 2008. St Vincent's Research Week 2008 Abstract Book, p 47.
7. Mageswaren E, Byron J, Proudman S, Gabbay E, Phung S, Roddy J, Youssef P, Nash P, Sahhar J, Stevens W. **Systemic Sclerosis in Australia: using the Australian Scleroderma Screening Program (ASSP) database to assist in assessment of cardiopulmonary complications.** Poster presented at St Vincent's Health Research Week 25-27 August 2008. St Vincent's Research Week 2008 Abstract Book, p 48.